Results 51 to 60 of about 73,909 (338)

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source

A study on the management of corticosteroid side effects in cancer patients [PDF]

, 2015
Background Systemic corticosteroids lead to many adverse effects especially in cancer patients. Preventive measures and treatment options are essential to minimise such side effects.
Fsadni, Clayton John
core  

Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik, Ainhoa Gomez‐Lumbreras, Guilherme Del Fiol, Kensaku Kawamoto, Katy E. Trinkley, Thomas Reese, Aubrey Jones, Daniel C. Malone   +7 more
wiley   +1 more source

Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease

Clinical Medicine Insights: Gastroenterology, 2017
Aim: To compare the efficacy and safety of omeprazole-domperidone combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD). Methods: In a comparative, randomized controlled, phase 4 study, outpatients with GERD were randomly ...
KY Marakhouski, GA Karaseva, DN Ulasivich, Y Kh Marakhouski   +3 more
doaj   +1 more source

Acid-suppressive effects of generic omeprazole: Comparison of three brands of generic omeprazole with original omeprazole [PDF]

Digestive and Liver Disease, 2006
Generic omeprazole contains the same active ingredient as original omeprazole and require verification of the bioequivalence with original omeprazole. However, very few clinical studies have been reported.A prospective, randomised, open-label, crossover study to compare acid-suppressive effect of generic omeprazole with that of original omeprazole ...
Shimatani, Tomohiko, Inoue, M., Kuroiwa, T., Xu, J., Mieno, H., Tazuma, S.   +5 more
openaire   +4 more sources

Stereotactic Magnetic Resonance-guided Online Adaptive Radiotherapy for Oligometastatic Breast Cancer: A Case Report. [PDF]

, 2018
We present a case of durable local control achieved in a patient treated with stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) for an abdominal lymph node in the setting of oligometastatic breast cancer.
Cao, Minsong, Dang, Audrey, Lamb, James, Lee, Percy, Low, Daniel A, Raldow, Ann C, Steinberg, Michael L, Tyran, Marguerite   +7 more
core   +1 more source

Mechanisms of Action Involved in the In Vivo Gastroprotective Response of Fruits: A Systematic Review

Food Frontiers, EarlyView.
ABSTRACT Gastrointestinal diseases remain a significant global health concern, primarily due to the limitations of current pharmacological treatments, which often come with adverse side effects and high recurrence rates. This situation highlights the urgent need for safer and more effective alternatives.
Isabel Sousa Alcântara, Renata Torres Pessoa, Lucas Yure Santos da Silva, Tarcisio Mendes Silva, Isis Oliveira Menezes, Anita Oliveira Brito Pereira Bezerra Martins, Irwin Rose Alencar de Menezes, Almir Gonçalves Wanderley   +7 more
wiley   +1 more source

Profiling and Identification of Omeprazole Metabolites in Mouse Brain and Plasma by Isotope Ratio-Monitoring Liquid Chromatography-Mass Spectrometric Method

Life, 2020
Neuro–inflammation is known to be one of the pathogenesis for the degenerative central nervous system (CNS) disease. Recently various approaches for the treatment of brain diseases by controlling neuro-inflammation in the brain have been introduced.
Seok-Ho Shin, Yuri Park, Min-Ho Park, Jin-Ju Byeon, Byeong ill Lee, Jangmi Choi, Young G. Shin   +6 more
doaj   +1 more source

Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM

The Journal of Clinical Pharmacology, EarlyView.
Abstract Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy
Samira Merali, Haden Bunn, Caroline Sychterz, Manting Chiang, Shilpa Puli, Amy J. Sehnert, Bindu Murthy, Joga Gobburu   +7 more
wiley   +1 more source